Heron Therapeutics Statistics
Total Valuation
HRTX has a market cap or net worth of $328.01 million. The enterprise value is $454.59 million.
Important Dates
The next estimated earnings date is Tuesday, August 5, 2025, after market close.
| Earnings Date | Aug 5, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HRTX has 152.56 million shares outstanding. The number of shares has increased by 4.72% in one year.
| Current Share Class | 152.56M |
| Shares Outstanding | 152.56M |
| Shares Change (YoY) | +4.72% |
| Shares Change (QoQ) | +28.58% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 59.67% |
| Float | 116.65M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 244.32 |
| PS Ratio | 2.22 |
| Forward PS | 2.69 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.06 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.40
| Current Ratio | 2.40 |
| Quick Ratio | 1.46 |
| Debt / Equity | n/a |
| Debt / EBITDA | 306.67 |
| Debt / FCF | n/a |
| Interest Coverage | -0.59 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -0.99% |
| Return on Invested Capital (ROIC) | -1.52% |
| Return on Capital Employed (ROCE) | -2.43% |
| Revenue Per Employee | $1.22M |
| Profits Per Employee | -$63,811 |
| Employee Count | 122 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.07 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -32.39% in the last 52 weeks. The beta is 1.17, so HRTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.17 |
| 52-Week Price Change | -32.39% |
| 50-Day Moving Average | 2.05 |
| 200-Day Moving Average | 1.87 |
| Relative Strength Index (RSI) | 57.88 |
| Average Volume (20 Days) | 1,197,148 |
Short Selling Information
The latest short interest is 33.96 million, so 22.26% of the outstanding shares have been sold short.
| Short Interest | 33.96M |
| Short Previous Month | 34.41M |
| Short % of Shares Out | 22.26% |
| Short % of Float | 29.11% |
| Short Ratio (days to cover) | 16.82 |
Income Statement
In the last 12 months, HRTX had revenue of $148.52 million and -$7.79 million in losses. Loss per share was -$0.06.
| Revenue | 148.52M |
| Gross Profit | 95.50M |
| Operating Income | -3.58M |
| Pretax Income | -48.13M |
| Net Income | -7.79M |
| EBITDA | -1.22M |
| EBIT | -3.58M |
| Loss Per Share | -$0.06 |
Full Income StatementBalance Sheet
The company has $50.68 million in cash and $177.26 million in debt, giving a net cash position of -$126.58 million or -$0.83 per share.
| Cash & Cash Equivalents | 50.68M |
| Total Debt | 177.26M |
| Net Cash | -126.58M |
| Net Cash Per Share | -$0.83 |
| Equity (Book Value) | -28.45M |
| Book Value Per Share | -0.19 |
| Working Capital | 124.28M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.88 million and capital expenditures -$1.82 million, giving a free cash flow of -$23.70 million.
| Operating Cash Flow | -21.88M |
| Capital Expenditures | -1.82M |
| Free Cash Flow | -23.70M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
Gross margin is 64.30%, with operating and profit margins of -2.41% and -5.24%.
| Gross Margin | 64.30% |
| Operating Margin | -2.41% |
| Pretax Margin | -5.24% |
| Profit Margin | -5.24% |
| EBITDA Margin | -0.82% |
| EBIT Margin | -2.41% |
| FCF Margin | n/a |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -4.72% |
| Shareholder Yield | -4.72% |
| Earnings Yield | -2.37% |
| FCF Yield | -7.22% |
Analyst Forecast
The average price target for HRTX is $5.00, which is 132.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.00 |
| Price Target Difference | 132.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 12.88% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 13, 2014. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
HRTX has an Altman Z-Score of -9.4 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.4 |
| Piotroski F-Score | 2 |
